LCTX CEO buys 15,000 shares in open market

Lineage Cell Therapeutics President and CEO Brian M. Culley reported an open-market purchase of 15,000 common shares at a weighted average price of $1.625 per share.

Rhea-AI Filing Summary

Lineage Cell Therapeutics President and CEO Brian M. Culley reported an open-market purchase of 15,000 common shares at a weighted average price of $1.625 per share. Following these purchases, he directly holds 255,516 common shares.

Insider Trade Summary

Net Buyer: 15,000 shares

Net Buy 1 txn

Insider Culley Brian M

Role President and CEO

Bought 15,000 shs ($24K)

Type	Security	Shares	Price	Value
Purchase	Common Shares	15,000	$1.625	$24K

Holdings After Transaction: Common Shares — 255,516 shares (Direct)

Footnotes (1)

1. F1. The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.61 to $1.63, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote 1.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did LCTX CEO Brian Culley report on this Form 4?

Brian Culley reported buying 15,000 LCTX common shares. The open-market purchase was executed at a weighted average price of $1.625 per share, increasing his direct ownership to 255,516 shares after the transaction.

At what prices did the LCTX CEO purchase shares in this transaction?

The CEO’s LCTX share purchases ranged from $1.61 to $1.63. The filing notes a weighted average price of $1.625 per share for the 15,000 common shares acquired in multiple transactions within that range.

How many Lineage Cell Therapeutics (LCTX) shares does the CEO own after this Form 4?

After the reported purchase, the CEO owns 255,516 LCTX shares. These are held as direct ownership of common shares, reflecting his position following the 15,000-share open-market acquisition disclosed in the filing.

Was the LCTX CEO’s Form 4 transaction a purchase or a sale of shares?

The Form 4 shows an open-market purchase of LCTX shares. Brian M. Culley bought 15,000 common shares, classified under transaction code “P,” which denotes a purchase in an open market or private transaction.

Does the LCTX Form 4 indicate any derivative or options activity for the CEO?

The Form 4 does not report any derivative transactions for the CEO. The filing only shows a non-derivative open-market purchase of 15,000 common shares, with no option exercises or other derivative activity disclosed in this report.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 03/12/2026 - 04:05 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Culley Brian M

(Last) (First) (Middle)

C/O LINEAGE CELL THERAPEUTICS

2173 SALK AVENUE, SUITE 200

(Street)

CARLSBAD CA 92008

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Lineage Cell Therapeutics, Inc. [ LCTX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	President and CEO

3. Date of Earliest Transaction (Month/Day/Year)
03/12/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Shares	03/12/2026		P		15,000	A	$1.625(1)	255,516	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.61 to $1.63, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote 1.

	/s/ Brian M. Culley	03/12/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.